Biopharma Genomic Testing Market Research

Project Overview

A diagnostic company wanted to assess the current and expected future landscapes for biopharma oncology genomics research and Dx / CDx

DeciBio Approach

Primary Research

Conducted telephone interviews with biopharma stakeholders director level and above involved in oncology R&D (translational and clinical research)
Conducted telephone interviews with biopharma CDx stakeholders director level and above (e.g., vice president of biomarker strategy)
Interviews were split by biopharma size with a majority at large biopharma

At a glance

Outcomes

DeciBio delivered a virtual final presentation that covered an in depth quantitative market analysis (e.g., landscape today, key trends, and expected future growth)

Quantitative assessment included:

Share of clinical trials employing prospective and / or retrospective genomic tests
Frequency of tests (e.g., therapy selection, MRD, treatment response monitoring) per patient
Test utilization by sample type, panel size, and (de)centralized models

Timeline

6 weeks

Geographic Scope

U.S.

Industry

Pharma & Biotech

capabilities

Voice-Of-Customer Research

Biomarker and Diagnostic Strategy

Biopharma Genomic Testing Market Research

Minimal Residual Disease (MRD) Application Prioritization and Evidence Generation Strategy

Methylation Analysis Opportunity Identification for Ultra-Sensitive Detection Platform

Biopharma Genomic Testing Market Research

Primary Research

Clinical, Genomic, and Pathology Real-World Data (RWD) Market Landscape Assessment

Internal Lab Buildout Strategy

Synthetic mRNA Production Landscape Assessment

AI Patient Recruitment Go-to-Market Strategy

Discover how we can help